Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study

Conclusions This study demonstrated that hyperphosphataemia developed quickly following the cessation of phosphate binders and remained persistently elevated in end-stage CKD in the placebo-treated group. Gradually titrating up sevelamer carbonate from an initial dose of 2.4 g/day to an average daily dose of 7.1 ± 2.5 g/day was well tolerated, safe and efficacious in contemporary Chinese haemodialysis patients.

http://ndt.oxfordjournals.org/cgi/content/short/29/1/152?rss=1

Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Chen, N., Wu, X., Ding, X., Mei, C., Fu, P., Jiang, G., Li, X., Chen, J., Liu, B., La, Y., Hou, F., Ni, Z., Fu, J., Xing, C., Yu, X., Huang, C., Zuo, L., Wang, L., Hunter, J., Dillon, M., Plone, M., Neylan, J. Tags: Chronic Kidney Disease Source Type: research